Diligence memo · auto-generated · as of July 2, 2026
Sutro Biopharma Inc
Sutro Biopharma Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Sutro Biopharma Inc operates in Biotechnology, based in SOUTH SAN FRANCISCO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sutro Biopharma Inc has raised $85M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $85M on 2018-05-24.
Most recent recorded round closed around 2018-05-24.
Valuation (modeled)modeled
Provath models Sutro Biopharma Inc at approximately $3.5B (range $264M–$9.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.71× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 8.1 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 89% of Biotechnology peers (4293 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Genesis Biopharma, Inc, Alder Biopharmaceuticals Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.